UK markets close in 3 hours 42 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
223.94+0.23 (+0.10%)
At close: 04:00PM EST
224.00 +0.06 (+0.03%)
Pre-market: 07:27AM EST
Full screen
Trade prices are not sourced from all markets
Previous close223.71
Bid222.48 x 900
Ask225.03 x 800
Day's range220.35 - 224.87
52-week range215.68 - 319.76
Avg. volume1,136,790
Market cap32.552B
Beta (5Y monthly)0.00
PE ratio (TTM)28.10
EPS (TTM)7.97
Earnings date23 Apr 2024 - 29 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est304.23
  • Insider Monkey

    14 Best Beaten Down Stocks To Buy Right Now

    In this piece, we will take a look at the 14 best beaten down stocks to buy right now. If you want to skip our coverage of the latest events in the stock market, then you can take a look at the 5 Best Beaten Down Stocks To Buy Right Now. The stock market of […]

  • Investor's Business Daily

    Is Eli Lilly Stock A Buy As Amgen Enters The Red-Hot Weight-Loss Ring?

    There's a growing field of competitors in the weight-loss drugs space, where Lilly and Novo currently dominate. Is Eli Lilly stock a buy?

  • GlobeNewswire

    Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

    SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field CAMBRIDGE, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opin